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In the last decades, astrocytes have risen from passive supporters of neuronal activity to
central players in brain function and cognition. Likewise, the heterogeneity of astrocytes
starts to become recognized in contrast to the homogeneous population previously
predicted. In this review, we focused on astrocyte heterogeneity in terms of their
morphological, protein expression and functional aspects, and debate in a historical
perspective the diversity encountered in glial progenitors and how they may reflect
mature astrocyte heterogeneity. We discussed data that show that different progenitors
may have unsuspected roles in developmental processes. We have approached the
functions of astrocyte subpopulations on the onset of psychiatric and neurological
diseases.
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Astrocyte Diversity
The human brain is acknowledged as the most complex of all organs, a structure dynamic enough
to adapt to dramatic environmental changes through plasticity occurring as a result of normal
physiology or during pathological events. Such complexity requires powerful homeostasis pro-
cesses to assure the perfect functioning of the system (Scuderi et al., 2013). Glial cells are pivotal to
maintain the structural integrity and functionality required by the central nervous system (CNS).
The so-called macroglia consists of a heterogeneous cell population, which comprises ependymal
cells, astrocytes, oligodendrocytes, andNG2 cells. Each of these cell populations is unique, although
sharing some properties.
The initial concept of macroglial cells as passive in brain function, working as a support-
ive element for the maintenance of neurons, has dramatically changed in the last quarter of a
century with an increased body of evidence showing active roles of glial cells in the transmis-
sion and integration of neural information (Wang and Bordey, 2008). In fact, macroglial cells are
directly involved in neuronal function through controlling neurogenesis, synaptogenesis, neu-
rotransmission, synaptic plasticity, neuronal growth, and neuron survival (Scuderi et al., 2013;
Zhang and Barres, 2013).
Astrocytes represent the most abundant macroglia and the largest and most heterogeneous
group of glial cell types. They participate in a wide variety of complex and essential functions in
the brain. For instance, astrocytes are responsible for the reuptake and release of transmitters,
distribution of water, pyruvate metabolism, removal of reactive oxygen species, and antioxi-
dant (glutathione) metabolism, organization of the blood brain barrier, ion buﬀering, synthesis,
and secretion of trophic factors and release of gliotransmitters through exocytosis mechanism
(Sofroniew and Vinters, 2010; Scuderi et al., 2013).
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Albeit the heterogeneity of functions and the prominent roles
they exert, astroglial cells have mostly been overlooked in the
quest to understand healthy and diseased brain functioning and
the classiﬁcation of astroglial cells still relies greatly on morpho-
logical criteria and use of few molecular markers.
Astrocytes are classically divided into two major subpopula-
tions in cerebral cortex: ﬁbrous astrocytes in the white matter
and protoplasmic astrocytes in the gray matter (Miller and Raﬀ,
1984). Fibrous astrocytes have long, thin processes, yielding a
star-like appearance. Protoplasmic astrocytes have many branch-
ing processes, which contact and ensheath synapses, and usu-
ally have one or two processes in contact with blood vessels.
However, this classiﬁcation is outdated in light of the great diver-
sity of astrocytes revealed by more detailed morphological and
biochemical analyses.
In fact, mature astrocytes can be identiﬁed by the expres-
sion of glial ﬁbrillary acidic protein (GFAP), calcium-binding
protein S100β, glutamate–aspartate transporter and glutamate
transporter 1 (GLT-1), and additional markers is recently
suggested based on microarray gene expression proﬁles
(Bachoo et al., 2004). Expressions of these markers, as well
as astrocyte morphologies, vary considerably amongst cor-
tical regions (Emsley and Macklis, 2006; Regan et al., 2007),
suggesting that astrocyte subpopulations could be diﬀeren-
tially speciﬁed to display distinct biochemical/biophysical
properties throughout discrete regions of the cerebral cortex
(Emsley and Macklis, 2006).
Astrocyte heterogeneity is also appreciated in other CNS
regions. Recent data suggest that the diﬀerential expression of
ionotropic receptors in thalamic astrocytes could indicate func-
tional heterogeneity. The thalamus, responsible for processing
sensory information relayed to the cortex, contains two diﬀerent
astrocyte populations regarding the expression of glutamatergic
receptors. Thalamic astrocytes isolated from postnatal transgenic
mice expressing human GFAP promoter under the control of
enhanced green ﬂuorescent protein (EGFP) were stimulated with
kainate, and kainate plus cyclothiazide (CTZ), an AMPA receptor
modulator. Only 60% of the cells stimulated showed enhanced
inward currents upon kainate and CTZ application (Hoft et al.,
2014). In addition, all astrocytes observed in electrophysiological
recordings showed K+ currents uponmuscimol stimulus, a selec-
tive agonist for the GABA-A receptor (Hoft et al., 2014). These
data indicate that astrocyte subpopulations diﬀerentially express
neurotransmitter receptors, reﬂecting a putative diﬀerence in
astrocytic function and physiology.
Using the same transgenic mice model above, two diﬀerent
populations of astrocytes were identiﬁed in hippocampal freshly
isolated cells or brain slices (Matthias et al., 2003). One popu-
lation of cells displays weak GFAP ﬂuorescence, thin and short
processes, whereas the second group of cells displays intense
GFAP-EGFP labeling and more complex process morphology
(Matthias et al., 2003). Besides morphology, the two groups of
cells diﬀer in their electric properties. In whole cell recordings,
the ﬁrst group of cells shows an outward rectifying K+ cur-
rent and the second one an inward K+ current (Matthias et al.,
2003). Application of glutamate or AMPA on weak ﬂuores-
cent GFAP cells evoke a fast and sensitized current whether
D-aspartate does not evoke any current, indicating expression
of AMPA receptors and lack of glutamate transporters. On
the contrary, the second group of cells has no kainate elicited
membrane currents, however, D-aspartate induce inward cur-
rents inhibited by the use of glutamate transporter blocker THA
(Matthias et al., 2003).
Investigation on the existence of astrocytes with qualita-
tively diﬀerent ion current phenotypes and morphology in the
hippocampus (Zhou and Kimelberg, 2000, 2001) and thalamus
(Hoft et al., 2014) suggest astrocyte heterogeneity by diverse
functional properties in diﬀerent populations of cells, some of
which expressing functional AMPA receptors and others gluta-
mate transporters (Matthias et al., 2003). Knowing the impor-
tance of neurotransmitters for the regulation of many signaling
pathways, further studies are relevant in order to reveal the
role of the diﬀerential expression of glutamatergic machinery
in astrocytes to physiological events such as cell migration and
diﬀerentiation.
A distinct feature of astrocytes is their extensive gap junctional
coupling. Gap junction communication is essential for signaling
in neuroglia circuit function in many brain regions. Therefore,
coupling diﬀerences among those regions could indicate astro-
cyte heterogeneity with possible functional diversity implications
(Froes and Menezes, 2002; Anders et al., 2014). Even more sub-
tle paradigms to measure dye diﬀusion via gap junction reveals
diﬀerences in astrocyte performance with temperature variance.
Experiments using the ﬂuorescent dye Alexa Fluor 594 to mea-
sure those parameters in CA1 and dentate gyrus of the rat
hippocampus (Anders et al., 2014) show that astrocyte coupling
may diﬀer between these regions in a temperature-dependent
manner, probably due to changes in intracellular diﬀusive prop-
erties, rather than measured by the number of astrocytes coupled
(Anders et al., 2014).
The Origin of Astrocytes
Gliogenesis generally follows neurogenesis in the developing
brain (Miller and Gauthier, 2007; Costa et al., 2009). However,
these events partially overlap and their precise temporal rela-
tionship in vivo and at the individual progenitor level remains
largely unexplored. Most macroglial cells in the rodent brain
are generated postnatally. In fact, during the ﬁrst 3 weeks of
cerebral cortex postnatal development, the macroglial cell pop-
ulation, which contains predominantly astrocytes, expands six-
to eightfold in the rodent brain (Bandeira et al., 2009).
As discussed above, astrocyte diversity in the brain becomes
increasingly recognized. Yet, it remains unclear whether astro-
cyte subtypes are generated from a homogeneous population of
progenitors or from separate classes of progenitors previously
speciﬁed within the germinative niches of the developing telen-
cephalon. Moreover, the developmental sequences undergone by
astrocyte precursors are only partially understood. We summa-
rize the main ﬁndings related to the generation of diﬀerentiated
astrocytes in the brain parenchyma.
Five diﬀerent sources of cortical mature astrocytes were
identiﬁed to date: (I) radial glia cell (RGC) within ventricular
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zone, (II) RGC transformation, (III) glial intermediate progen-
itors (GP) within subventricular zone, (IV) GPs present in the
marginal zone (MZ)/layer 1, (V) superﬁcial layer progenitors. A
schematic view of astrogliosis to the cerebral cortex is illustrated
in the Figure 1.
(I, II and III) Astrocytes Derived from Radial
Glia Cell Directly, or by Direct
Transformation or by the Generation of
Intermediate Progenitors
One of the earliest and most understood source of astrocytes in
the cerebral cortex is the direct transformation of RGCs into pro-
toplasmic astrocytes that occurs, at the end of cortical neurogen-
esis, after birth in diﬀerent species (Schmechel and Rakic, 1979;
Voigt, 1989; Alves et al., 2002; deAzevedo et al., 2003). During
this process, RGCs lose their apical process and move toward the
pial surface, eventually undergoing mitosis in the subventricular
zone (SVZ; Noctor et al., 2004). It is likely that these transform-
ing and proliferating cells represent at least a fraction of the
GPs labeled by retrovirus in the SVZ and studied in previous
work (Levison et al., 1993), what could help to explain the little
dispersion of clonally related astrocytes (Magavi et al., 2012).
Radial glia cells generate intermediate progenitors through
asymmetric division within the SVZ. These glial intermediate
progenitors also divide and give rise to immature proliferative
astrocytes that migrate radially out of the germinative zone and
populate the cerebral parenchyma (Levison and Goldman, 1993;
Levison et al., 1993; Luskin and McDermott, 1994; Zerlin et al.,
1995). When they reach their destination, the immature cells still
proliferate and only later fully diﬀerentiate into mature astrocytes
(Ge et al., 2012).
Interestingly, retroviral-mediated fate mapping of postnatal
SVZ progenitors indicate that white and gray matter astro-
cytes, as well as oligodendrocytes derive from separate macroglial
progenitors (Luskin and McDermott, 1994) and that astrocytes
generated in the SVZ do not disperse long distances in
the rostro-caudal axis (Levison et al., 1993), instead they are
regionally restricted. This regionalization may start at earlier
time points, as indicated by recent work (Magavi et al., 2012;
FIGURE 1 | Origins of astrocytes in the cerebral cortex. (A) At later stage
of embryonic brain development radial glial cell (RGC), in the ventricular zone
(light gray region), gives rise to astrocytes (AS) that disperse throughout the
ventral forebrain parenchyma (dark gray region). (B) After birth, RGC loses their
apical processes and directly transform into cortical astrocytes. (C) Glial
progenitor (GP) derived from RGC undergoes cell division in the subventricular
zone (light gray region) generating astrocytes that disperse radially to the cortical
layers (dark gray region) and white matter (white region). Astrocyte proliferates
locally amplifying the astrocytic population. GP present in the Marginal Zone
(MZ)/Layer 1 (Dotted region) contributes to superficial cortical astrocyte.
(B/C) During embryonic development dorsal RGC also generates pyramidal
neurons (PN) that migrate radially and settle in individual cortical columns in the
gray matter. Observe that developing astrocytes maintain the columnar
organization with early generated neurons. Dashed lines indicate the boundaries
of individual cortical columns. Black filled figures represent mitotic cells. RGC,
radial glia cell; AS, astrocyte; GP, glial progenitor; PN, pyramidal neurons.
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Garcia-Marques and Lopez-Mascaraque, 2013; Gao et al., 2014).
Using a novel genetic tool for tracing GP lineage, the so-
called “Star Track,” which uses a combinatorial expression of
six ﬂuorescent proteins under the control of GFAP promoter,
Garcia-Marques and Lopez-Mascaraque (2013) show that clon-
ally related astrocytes disperse radially in the cortex spanning
the entire depth of the cortical parenchyma. Similarly, when
individual cortical RGCs are labeled at early embryonic stages
using genetic strategies, they give rise to discrete columnar
structures that contain both projection neurons and proto-
plasmic astrocytes in the adult animals (Magavi et al., 2012;
Gao et al., 2014). Most columns of neurons contained multiple
clusters of astrocytes, and the vast majority of labeled astro-
cytes were found within 50 μm of a labeled neuronal col-
umn. The astrocyte to neuron ratio in a single developmen-
tal column was similar across the entire neocortex, indicating
that column-associated astrocytes account for the majority of
protoplasmic astrocytes in the neocortex. Together these data
suggest that cortical protoplasmic astrocytes are generated in
a spatially restricted manner from progenitors that also give
rise to columns of pyramidal neurons (PNs) during embryonic
development.
Notably, cortical excitatory neurons are spatially organized
into individual cortical columns, which are involved in the pro-
cessing of similar sensory stimuli (Mountcastle, 1997). It is
hypothesized that the generation of neuronal cortical columns
could be controlled by transcriptional codes expressed in progen-
itor cells at early development (Costa and Hedin-Pereira, 2010)
and it is tempting to speculate that the columnar organiza-
tion of astrocytes in the cerebral cortex (Magavi et al., 2012)
could also reﬂect some degree of spatial speciﬁcation in GPs.
Some evidence of this was found in spinal cord where astro-
cytes have been shown to be regionally speciﬁed (Hochstim et al.,
2008). In this work, the authors describe three distinct subtypes
of astrocytes which could be distinguished by the combinato-
rial expression of Reelin and Slit1 (Hochstim et al., 2008). These
astrocyte subtypes originate from separate progenitor domains
expressing the transcription factors Pax6 and Nkx6.1, suggesting
that astrocyte diversiﬁcation could be regulated within progeni-
tors.
Another example of speciﬁc progenitors which generate spa-
tially restricted astrocyte subpopulations comes from lineage
studies of ventral telencephalon NG2 cells. It is found that
ventral embryonic NG2 cells, derived directly from RGCs, gen-
erate a subset of protoplasmic astrocytes only to the ventral
forebrain, but no astrocytes to the dorsal cortex or cortical
white matter, e.g., corpus callosum. (Marshall and Goldman,
2002; Belachew et al., 2003; Zhu et al., 2008, 2012; Huang et al.,
2014). Moreover, embryonic NG2 cells only generate astro-
cytes within the forebrain, since no labeled astrocytes were
found in other brain regions (Huang et al., 2014). Thus astrogli-
ogenic potential of NG2 cells seems to be temporal and spa-
tially conﬁned to a subgroup of ventral embryonic progeni-
tors.
On the other hand, dorsal cortical astrocytes are mostly gen-
erated from an Emx1-expressing progenitor (Gorski et al., 2002),
which is a transcription factor regionally expressed by cortical
progenitors in the dorsal VZ/SVZ (Gulisano et al., 1996). Using
a conditional double transgenic mouse reporter to trace Emx1-
cell lineage, the authors show that the vast majority of, if not
all, cortical excitatory neurons and astrocytes generated postna-
tally is derived from Emx1-expressing cells (Gorski et al., 2002).
Thus ventral and dorsal forebrain astrogliogenesis are temporal
and spatially conﬁned to a subgroup of GPs. While subpallial
astrocytes are dependent on NG2-expressing progenitors, pallial
astrocytes rely on Emx1-expressing progenitors.
(IV) From Glial Progenitors Present in the
Marginal Zone/Layer 1
In the embryonic and neonatal MZ/layer 1, a separate class
of progenitors undergoes cell division and contributes with
astrocytes, oligodendrocytes, and neurons to the cerebral cor-
tex (Costa et al., 2007; Breunig et al., 2012) and therefore is
described as a novel niche for gliogenesis and neurogenesis in
the cerebral cortex. MZ/layer 1 progenitors are derived from
ventral (progenitors expressing the transcription factors Nkx2.1
or Gsh2) and dorsal telencephalic ventricular zone (progenitors
expressing the transcription factors Emx1), with a predomi-
nance of the latter at neonatal stage (Costa et al., 2007). Given
the unique composition of the MZ/layer 1, it is possible that
local proliferation in this region contributes to the generation
of astrocyte diversiﬁcation in the cerebral cortex (Costa et al.,
2007). Actually, evidence from human embryonic cortex shows
that diﬀerent morphologies and developmental stages charac-
terize superﬁcial and deep astrocytes (deAzevedo et al., 2003).
Whilst deep astrocytes emerge by the process of RGC trans-
formation in the subplate of human cingulate cortex, superﬁ-
cial astrocytes labeled for GFAP are already present in the MZ
and dorsal supragranular layers in the second half of gesta-
tion. At this point no GFAP-positive cells can yet be labeled
in human cortical plate. The ﬁrst GFAP-positive cells to be
labeled within the human cortical plate appear associated with
blood vessels (Marin-Padilla, 1995; deAzevedo et al., 2003) rais-
ing the question of whether angiogenesis might have a piv-
otal role in the appearance of gray matter astrocytes. While
in humans GFAP is a conventional marker for RGCs and
astrocytes, in rodents this labeling is restricted, bringing our
attention to the evolutionary diﬀerences in the glial popula-
tion between rodents and primates, for example (Takahashi et al.,
1990; deAzevedo et al., 2003).
(V) Superficial Layer Progenitors
Local proliferation was the main focus on a recently study of
Ge et al. (2012). They show that GPs and RGC transforma-
tion combined contribute to mature astrocyte diﬀerently when
observed superﬁcial and deeper cortical layers. While both
sources generate most of the astrocytes to deep cortical layers
(layers 5–6) and white matter astrocytes, 97% of labeled pro-
genitors, only 3% of these progenitors are dedicated to upper
cortical layers (layers 1–4). Using retrovirus injected in the cortex
of postnatal mice, the authors labeled dividing cells and pro-
vide evidence, at least to superﬁcial cortical layers, that local
proliferation of immature astrocytes is responsible to expand
the cell population. It is possible that local proliferation in
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deeper cortical layers and white matter may also occur. However,
more striking is to determine whether this diﬀerential astro-
cyte dispersion through cortical layers confers a distinct glial
function within neuronal circuitries. It is also unclear whether
these locally proliferating astrocytes are derived from GPs in the
MZ/Layer 1.
Future experiments should address more directly the ques-
tion of whether positionally and functionally distinct sub-
types of astrocytes in the forebrain develop from previously
speciﬁed sets of progenitors and the degree of plasticity of
GPs when proliferating in diﬀerent environments, such as
MZ/Layer 1, deep and superﬁcial cortical layers, or white matter.
These studies may also shed light on our understanding about
the mechanisms subsidizing neurological and psychiatric dis-
eases in which astrocytes are aﬀected at subpopulation distinct
manner.
Astrocytes and Disease
Given the diversity of astrocytes and their pleiotropic functions, it
is not surprising that their dysfunction is also an important mat-
ter to several neurological disorders. However, the involvement of
this type of glia in pathological conditions became only recently
clear due to a steadily increasing interest in the study of the biol-
ogy and pathology of astrocytes (Sofroniew and Vinters, 2010).
It is tempting to speculate that diﬀerent subtypes of astrocytes
would contribute to the onset or progression of brain diseases.
And evenmore, only a subset of astrocytes would be diﬀerentially
aﬀected by the microenvironment of the diseased brain.
The response of astroglia in pathological conditions is very
heterogeneous. Indeed, in some circumstances, it is possible
to observe morphological changes of these cells that become
hypertrophic and proliferate, leading to the so-called reactive
gliosis state. In these conditions, astrocytes can release diﬀer-
ent kinds of cytokines with either pro-or anti-inﬂammatory
potential (Sofroniew and Vinters, 2010). Other pathologi-
cal situations are characterized by astro-degeneration with
consequent loss of their physiological supportive functions
(Scuderi et al., 2013). Nowadays, there is increasing evi-
dence of astrocytic dysfunction in several brain disorders.
The homeostatic failure due to astrocyte degeneration can
be fundamental for the initiation and progression of neu-
ropathological diseases. There is an increasing body of evidence
showing the contribution of astrocytes in schizophrenia
(Kolomeets and Uranova, 2010; Schnieder and Dwork, 2011),
autism (Laurence and Fatemi, 2005; Bristot Silvestrin et al.,
2013), and drug abuse (Beardsley and Hauser, 2014; Bull et al.,
2014; Jackson et al., 2014). Astrocyte dysfunction is also involved
in major depression disease and neurodegenerative disorders
such as Alexander Disease (AxD), Amyotrophic Lateral Sclerosis
(ALS), and Alzheimer’s Disease (AD), focused on this review.
Although astrocytes present a common reaction to the lesioned
nervous system with the upregulation of GFAP for example,
we will see in the following session that there is enormous
diversity in astrocyte response that may be accounted for by
environmental diﬀerences or by astrocyte heterogeneity.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis is a neurodegenerative disease that
is characterized by the loss of corticospinal and spinal motor neu-
rons. Multiple genes are linked to this disorder, but the discovery
of mutations in the Cu-Zn superoxide dismutase (SOD1) led to
the generation of transgenic animal models that have contributed
to current knowledge on ALS pathology. Evidence support a cen-
tral role for neuro–glia interactions suggesting that glial cells,
and in particular astrocytes, could be a target for novel therapy
in ALS (Valori et al., 2014). In fact, massive activation of astro-
cytes and microglia is associated with motor neuron death in
humans, as well as in transgenic animal models (Boillee et al.,
2006; Yamanaka et al., 2008). However, selective ablation of pro-
liferating GFAP-expressing astrocytes and microglia fail to mod-
ify disease progression (Gowing et al., 2008; Lepore et al., 2008).
Using SOD1G93A transgenic (SOD–Tg) rats, Barbeito and col-
laborators isolated in culture a new type of astrocyte from
adult spinal cord of symptomatic animals (Diaz-Amarilla et al.,
2011). SOD–Tg-derived astrocytes reached conﬂuence rapidly
and could be propagated for 1 year in culture. Because of this fea-
ture they were called “aberrant astrocytes” (AbA cells), which are
highly proliferative and appear to drive motor neuron death in a
cell-type speciﬁc fashion in vitro (Diaz-Amarilla et al., 2011).
Aberrant astrocytes cells are almost undistinguishable mor-
phologically from primary neonatal astrocytes. They express a
set of distinctive antigenic markers of undiﬀerentiated astrocytes
including intense staining for S100β in the cell nucleus and cyto-
plasm, high connexin 43 expression and low levels of diﬀuse per-
inuclear labeling of non-ﬁlamentous GFAP (Diaz-Amarilla et al.,
2011). This low expression of GFAP could be partially respon-
sible for failure observed in earlier studies, which aimed to
control proliferation of GFAP-expressing astrocytes in ALS
lesion.
Interestingly, AbA cells do not express detectable GLT-1, a
speciﬁc glial glutamate transporter, what could explain further
excitotoxic damage to motor neurons in vivo. Moreover, the neu-
rotoxicity of AbA cells conditioned medium is speciﬁc to motor
neurons (Diaz-Amarilla et al., 2011). This cell-type speciﬁc inter-
action has been already reported for mutant SOD1 expressing
primary astrocytes, which reduce viability of both primary and
embryonic stem cell-derived motor neurons in co-culture, but
not interneurons or dorsal root ganglion neurons (Nagai et al.,
2007).
In culture, AbA cells also show increased proliferation and lack
of replicative senescence, suggesting there is a defect in contact
inhibition, but they do not appear to be fully transformed cells
(Diaz-Amarilla et al., 2011). Additionally S100β expression did
not co-localize with NG2-labeling cells, which proliferate in the
ALS spinal cord (Kang et al., 2010), suggesting that the dividing
S100β-positive cells constitute a diﬀerent cell population that is
not derived from NG2 cells. Recently, it was found that AbA cells
are most likely derived from activated microglia present in the
spinal cord lesion (Trias et al., 2013). After two weeks in culture,
SOD-Tg-derived microglia cells start their transformation into
astrocytes. Thus, a subpopulation of microglia in culture loses its
markers, such as Iba1 and CD163, and increases the expression of
the astrocyte markers GFAP and S100β. Changes in the protein
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proﬁle are also followed by phenotypical alterations (Trias et al.,
2013). This ﬁnding raises a novel perspective on astrocyte studies
in ALS disease, which should then consider impeding the trans-
formation of microglia into astrocyte-like cells as a therapeutic
strategy.
For all these evidence, authors suggest that AbA cells may
be considered a distinct subpopulation of highly toxic astrocytes
generated during recruitment and phenotypic transition of glial
cells in an inﬂammatory microenvironment. And since astrocytes
are involved in the rapid progression of paralysis characteristic of
the ALS animal model, AbA cells could represent an additional
cellular target for future treatment of ALS (Diaz-Amarilla et al.,
2011; Trias et al., 2013).
Alexander Disease
Alexander disease is an autosomal dominant leukodys-
trophy, which predominantly aﬀects infants and children
(Goyal et al., 2014; Verkhratsky and Parpura, 2014). It is an
inherited gliopathology, associated with sporadic mutations
in the GFAP encoding gene that was ﬁrst described in 1949
by Stewart Alexander (Alexander, 1949; Brenner et al., 2001;
Verkhratsky and Parpura, 2014). Those pathogenic mutations
are thought to confer cytotoxicity through gain-of-function
mechanisms (Brenner et al., 2001; Prust et al., 2011). The
impaired function of astroglia aﬀects brain development
and results in progressive failure of central myelination,
developmental delay, seizures, megalencephaly, and pro-
gressive deterioration, with increased severity in neonatal
patients (Prust et al., 2011; Verkhratsky and Parpura, 2014).
Histopathological analysis shows that AxD is associated with
the appearance of cytoplasmic inclusions in astroglial cells
known as the Rosenthal ﬁbers (Verkhratsky and Parpura, 2014).
These are protein aggregates containing GFAP, ubiquitin, heat
shock protein hsp-27, and B-crystallin and they are expressed in
astrocytes adjacent to areas of demyelination (Goyal et al., 2014).
Observation that Rosenthal ﬁber formation can be induced
by the overexpression of human GFAP in transgenic mice in
a dose dependent manner (Messing et al., 1998; Quinlan et al.,
2007) lead to the search for mutations in the GFAP gene.
Gfap encodes for an intermediate ﬁlament protein that can
be alternatively spliced (Quinlan et al., 2007). Relative abun-
dance of GFAP transcripts is often low, dependent on astro-
cyte location, and induced by disorders (Roelofs et al., 2005;
Kamphuis et al., 2012, 2014), suggesting an interesting source
for astrocyte heterogeneity. Brenner et al. (2001) found that the
genetic mechanism of AxD is based in the de novo muta-
tions in four diﬀerent GFAP residues, R79, R239, R258, and
R416 observed in 12 unrelated individuals. In addition, other
investigators found several spots for mutations in GFAP gene
in early and later onset, indicating dominant missense GFAP
mutations for nearly all forms of this disorder (Li et al., 2005;
Quinlan et al., 2007). The genetic basis for AxD is now very
well established, however, little is known about the mecha-
nisms by which GFAP mutations lead to disease. To under-
stand how the pathology progresses, transgenic mice over-
expressing wild type GFAP that develop an encephalopathy
with identical aggregates present in AxD were analyzed in
diﬀerent phases by microarray assays (Hagemann et al., 2005;
Quinlan et al., 2007). Transcription proﬁles reveals alteration in
genes involved in stress and immune responses (Hagemann et al.,
2005). At 3 months age, transgenic mice show stress responses
including increase in genes expression involved in glutathione
metabolism, peroxide detoxiﬁcation, and iron homeostasis
(Hagemann et al., 2005). GFAP overexpression in those mice
also induces an increase in activation of cytokine, cytokine
receptor genes, and complement components. These transcripts
are further elevated with age, with additional induction of
macrophage-speciﬁc markers, suggesting activation of microglia
(Hagemann et al., 2005; Quinlan et al., 2007). At 4 months,
in contrast to those genes showing increased expression at
3 months, there is a decrease in expression of microtubule-
associated proteins (Hagemann et al., 2005). Numerous genes
involved in neurotransmission and vesicular transport are also
downregulated including both GABA and glutamate receptors
(Hagemann et al., 2005; Quinlan et al., 2007). The transcrip-
tional proﬁles from olfactory bulb also show a decrease in
transcriptional factors and signaling molecules involved in neu-
rogenesis such as Dlx family genes (Hagemann et al., 2005).
Therefore, this completely remodeled scenario aﬀects neuron-
glia signaling, leading to neuronal dysfunction in advanced stages
of pathology.
Alzheimer’s Disease
Neurodegenerative disorders such as AD are the most common
diseases of modern society. The gradual and irreversible dis-
turbances in homeostasis, leading to synaptic dysfunction and
cognition impairment are characteristic features of the disease.
Symptomatically, AD is characterized by marked deﬁciencies in
episodic memory, attention, perception, reasoning, and language
as well as altered mood (Mesulam, 1999; Hancock et al., 2014).
Pathologically, it is deﬁned by the accumulation of intracellular
neuroﬁbrillary tangles, comprised of abnormally phosphorylated
tau protein and extracellular plaques, including misfolded forms
of the amyloid-β (Aβ) peptide within the brain (Mesulam, 1999;
Hancock et al., 2014).
The overall assumption in AD is that astrocyte response
involves a generalized overexpression of GFAP and an increase
in proliferation. However, a growing body of evidence shows that
there are two diﬀerent populations of astrocytes in AD, reveal-
ing the heterogeneity in cell response upon diﬀerent stimuli and
environment.
Studies from a triple transgenic mouse model of AD, which
mimics the progression of the disease in humans, show that
the patterns of GFAP expression diﬀer among brain areas and
during the diﬀerent phases of the neurodegenerative process
(Olabarria et al., 2010; Yeh et al., 2011). The number of GFAP-
positive astrocytes does not change with the age of the transgenic
animals, however, in mice from 6, 12, and 18 months there
is a reduction in volume and area of GFAP-expressing cells in
the dentate gyrus, indicating astrocyte atrophy (Olabarria et al.,
2010). However, in Aβ plaque surrounding areas, there is an
opposite proﬁle of GFAP expression, observed by an increase
in GFAP volume and superﬁcial expression pattern in the den-
tate gyrus and CA1 regions, demonstrating a hypertrophy of
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astrocytes (Olabarria et al., 2010). Therefore, two diﬀerent pop-
ulations of astrocytes are revealed in AD. This concomitant
astrocyte atrophy and astrogliosis in AD does not seem to occur
in all brain regions. Analyses of the entorhinal cortex, a funda-
mental structure for cognitive and memory processes, show that
in the triple transgenic mouse model of AD, there is a reduction
in primary and secondary branches accompanied by a decrease
in volume and area of GFAP expression. These morphological
changes are observed in 1 month old animals and persist up
to 12 months (Yeh et al., 2011). The progression of the disease
established by the accumulation of Aβ deposits does not trigger
a reactive gliosis, indicating an absence of astrocytic hypertrophy
during AD in the entorhinal cortex (Yeh et al., 2011).
Another brain area involved in the symptomatology of AD
is the medial prefrontal cortex, which is associated with cogni-
tive, memory, and emotional processes. In this brain area, the
number of GFAP-positive cells does not change signiﬁcantly with
age as compared to wild type mice (Kulijewicz-Nawrot et al.,
2012). However, at 3 months, transgenic mice show astroglial
cytoskeletal atrophy that remains throughout the disease progres-
sion (Kulijewicz-Nawrot et al., 2012). Reduction in volume and
area of GFAP-positive proﬁles in the medial prefrontal cortex
show a clear layer-speciﬁc pattern, with layers 1–2 being strongly
aﬀected and similar changes being found in the deep layers 4 and
5, while layer 3 is only aﬀected from intermediary phases of the
disease progression (Kulijewicz-Nawrot et al., 2012). In contrast
to other brain regions aﬀected in AD, such as the hippocampus
(Olabarria et al., 2010; Yeh et al., 2011), no plaque formation is
observed in medial prefrontal cortex (Kulijewicz-Nawrot et al.,
2012). However, the Aβ aggregates are present, especially in
the deeper layers. Those ﬁndings show that astrocytic atrophy
occurs in early stages of the disease in speciﬁc brain areas. This
alteration of astrocytes may represent a very relevant aspect for
the progression of the disease. Astrocytic dysfunction compro-
mises brain homoeostasis on many levels, reducing brain energy
and neurotransmitter homoeostasis, increasing excitotoxicity. In
addition, atrophied astrocytes can reduce synaptic coverage, lead-
ing to a decrease in number and functional synapses, decreased
connectivity, imbalanced neurotransmission, synaptic strength,
and synaptic maintenance. These data indicate that astrocytes
within distinct brain regions may respond in a very peculiar
manner to similar stimuli, supporting the view that astrocytes
are heterogeneous and play diﬀerent roles in disease progres-
sion.
At later stages of the AD, the astrocytic morphology is com-
plex. There is formation of senile plaques resulting in astrogliosis
revealed by astrocytic hypertrophy, thicker processes, increased
volume and area of GFAP-positive proﬁles surrounding Aβ
deposits (Olabarria et al., 2010).
Neuropathology data using human brains show that astrocytes
activated by Aβ (Scuderi et al., 2013) secrete pro-inﬂammatory
signals and toxic cytokines that lead to further damage, increas-
ing nitric oxide radicals and TNF-α levels, which in turn
triggers a neurodegenerative cascade (Zhang et al., 2010). The
inﬂammation itself can lead to neuronal dysfunction, indepen-
dently of cell death. The parallel pro-inﬂammatory cytokine
network induces dysfunction in astrocytes in their eﬀort to
maintain environment homeostasis, which in turn increases
neuronal vulnerability. Thus, astrocyte impairment can occur
during early and late stages of the disease depending on the
brain region and how astrocytes modulate GFAP expression
and the secretion of cytokines or trophic factors in response to
stimuli.
Glial ﬁbrillary acidic protein gene can be alternatively spliced
and the canonical isoform GFAP-α expressed in astrocytes con-
tains nine exons (Kamphuis et al., 2012, 2014). So far, nine iso-
forms are described in diﬀerent species (Kamphuis et al., 2012).
Three splice variants GFAPDEx6, GFAPD164, and GFAPD lack-
ing sequences in exons 6–7 are found in AD (Hol et al., 2003).
GFAP transcripts from alternative splicing have variable alter-
ations in their C-terminal region. The C-terminal region is
important to direct the assembly of GFAP ﬁlaments and their
interaction to other proteins (Kamphuis et al., 2014). Thus, dif-
ferent C-terminals lead to diﬀerent GFAP expression patterns
and cellular functions. Evidence that GFAP can be translated
from diﬀerent transcripts corroborates the idea that astrocytes
are distinct cells populations with a speciﬁc transcriptional
regulation repertoire leading to putative diﬀerences in their
function.
Major Depression Disorder
Major depressive disorder (MDD) is one of the most preva-
lent mood disorders, aﬀecting millions of people worldwide.
MDD is a chronic, recurrent and debilitating mental illness, char-
acterized by core symptoms such as depressed mood, loss of
interest or pleasure, changes in weight and in sleep, fatigue or
loss of energy, feeling of worthlessness, concentration diﬃculties,
and thoughts of death or suicide (Rajkowska and Stockmeier,
2013). Several hypotheses including chronic stress, failure of
hippocampal neurogenesis in the adult, altered neuroplastic-
ity, dysfunction of monoaminergic systems and genetic fac-
tors have been studied to elucidate depressive-related behaviors
(Smialowska et al., 2013). The general knowledge about depres-
sion was originally taken from studies showing impairment in
the monoamine system and is supported by the understand-
ing of both the pathophysiology of depression and the action of
pharmacological treatments. However, in the past few years, this
concept related to monoamines has shifted to a putative deﬁcit
in glutamatergic signaling contributing to depressive symptoms
(Catena-Dell’Osso et al., 2013; Smialowska et al., 2013). Indeed,
the use of ketamine, a N-methyl-D-aspartate (NMDA) receptor
antagonist, provided the most promising results in preclinical
studies and produced a consistent and rapid, although transient,
antidepressant eﬀect with a good tolerability proﬁle in humans
(Catena-Dell’Osso et al., 2013).
Astrocytes play a remarkable range of roles to maintain home-
ostasis and optimum neuronal function. As mentioned before,
astrocytes can remove the excess of K+ and water, reuptake and
release neurotransmitters, secrete trophic factors, and regulate
metabolic pathways. Astroglial cells are the most important cells
in the balance of glutamate and GABA signaling due to their
ability to uptake those transmitters, control their release and to
provide glutamine for glutamate and GABA synthesis. Therefore,
astroglial homeostatic cascades are neuroprotective and can
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prevent neuronal damage by maintaining brain metabolism and
attenuating excitotoxicity through removal of glutamate excess
(Verkhratsky et al., 2014).
Histopathological studies from postmortem brain tissue reveal
prominent glial pathology in MDD. Astroglial changes are
represented by a decrease in density of astrocytes stained
by Nissl technique as well as a decrease in the num-
ber of GFAP-positive astrocytes (Rajkowska and Stockmeier,
2013). These alterations in astrocyte number and morphol-
ogy are observed in many brain regions from MDD sub-
jects. Cortical layers from prefrontal cortex (Cotter et al., 2002),
orbitofrontal cortex, subgenual cortex (Ongur et al., 1998),
anterior cingulate cortex (Cotter et al., 2001) the hippocam-
pus, and the amygdala (Ongur et al., 1998; Bowley et al., 2002;
Rajkowska and Stockmeier, 2013; Verkhratsky et al., 2014) were
analyzed with diﬀerent methodologies and display glia reduction
and or morphology alteration (Verkhratsky et al., 2014). Increase
in the levels of S100β in blood serum of MDD patients, which
is attenuated by antidepressant treatment is another evidence
of astrocyte degeneration in the disease (Schroeter et al., 2002;
Smialowska et al., 2013).
In contrast to these data, MDD elderly subjects show
an increase in GFAP density in cortical layers 3, 4, and
5 of dorsal prefrontal cortex compared to younger MDD
patients (Miguel-Hidalgo et al., 2000; Verkhratsky et al., 2014).
Indeed, cingulate cortex and orbitofrontal from MDD elderly
patients did not show any reductions in GFAP expression
(Khundakar et al., 2011a,b; Rajkowska and Stockmeier, 2013),
indicating a possible diﬀerence in GFAP expression upon aging.
There is some evidence that do not conﬁrm GFAP reduc-
tion in MDD. Results from entorhinal cortex show no alter-
ations in density and GFAP morphology in MDD subjects
(Damadzic et al., 2001). Torres-Platas et al. (2011) demonstrates
a hypertrophy in white matter astrocytes in studies from post
mortem samples of anterior cingulate cortex of suicide sub-
jects. This observation corroborates data showing inﬂamma-
tory processes underlying MDD pathology (Maes et al., 2009;
Rajkowska and Stockmeier, 2013). In general, apart from data
associated with aging or inﬂammation, there is a decrease
in GFAP expression and other related glial markers in
brain areas associated with mood disorders (Smialowska et al.,
2013).
Reduction of the number of GFAP-positive cells in MDD
patients is accompanied by a reduction in the expression of sev-
eral genes involved with glutamate signaling, mainly expressed
in astrocytes in the locus coeruleus (Bernard et al., 2011). In
situ hybridization data from animal models of MDD also show
a reduction in the expression of the GLT-1 in the hippocam-
pus and cerebral cortex (Zink et al., 2010), suggesting a dys-
function in glutamate reuptake, glutamine synthesis and in
the glutamate-GABA shunt, possibly underlying the pathology
of MDD (Rajkowska and Stockmeier, 2013; Verkhratsky et al.,
2014).
Expression of aquaporin 4 and connexins (Cx30 and Cx43) is
also reduced in cortical and subcortical astrocytes in both MDD
and in an experimental stress model (Rajkowska and Stockmeier,
2013; Verkhratsky et al., 2014). Accordingly, work by Sun et al.
(2012) shows that animals submitted to unpredictable stress, a
rodent model of depression, exhibited signiﬁcant decrease in dif-
fusion of gap junction channel permeable dye and expression of
Cx43. Furthermore, injections of carbenoxolone, a blocker of gap
junctions, into the prelimbic cortex induce anhedonia and anx-
iety in mice submitted to diﬀerent behavioral tests (Sun et al.,
2012). These data suggest that alteration in mice behavior related
toMDD pathophysiology may involve astrocytic communication
failure, at least in part, since CBX is an unspeciﬁc blocker. This
altered scenario can be crucial for the information processing and
the establishment of MDD pathophysiology (Verkhratsky et al.,
2014).
Conclusion
Taken together, many of the cellular and molecular markers for
astrocyte heterogeneity were shown to be key players in astrocyte
mediated disease processes. However, the precise role of diﬀer-
ent astrocyte populations in disease onset and progression still
remains to be addressed.
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